您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Zonisamide(AD 810 CI 912)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Zonisamide(AD 810 CI 912)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Zonisamide(AD 810 CI 912)图片
CAS NO:68291-97-4
规格:≥98%
包装与价格:
包装价格(元)
50mg电议
100mg电议
250mg电议
500mg电议
1g电议
10g电议

产品介绍
Zonisamide (AD810; CI912; AD-810; CI-912), an antiepileptic drug, is a voltage-dependent sodium channel and T-type calcium channel blocker. Zonisamide is a sulfonamide anticonvulsant approved for use as an adjunctive therapy in adults with partial-onset seizures; infantile spasm, mixed seizure types of Lennox–Gastaut syndrome, myoclonic, and generalized tonic clonic seizure. Zonisamide modifies dopamine (DA) activity, provides protection in ischemia mice models and influences antioxidant systems. Zonisamide attenuates the reduction in striatal contents of DA, its metabolite DOPAC and tyrosine hydroxylase (TH).
理化性质和储存条件
Molecular Weight (MW)212.23
FormulaC8H8N2O3S
CAS No.68291-97-4
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 42 mg/mL (197.9 mM)
Water:<1 mg/mL
Ethanol: 5 mg/mL (23.6 mM)
Other info

Chemical Name: benzo[d]isoxazol-3-ylmethanesulfonamide

InChi Key: UBQNRHZMVUUOMG-UHFFFAOYSA-N

InChi Code: InChI=1S/C8H8N2O3S/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7/h1-4H,5H2,(H2,9,11,12)

SMILES Code: O=S(CC1=NOC2=CC=CC=C12)(N)=O

SynonymsAD-810; CI-912; AD810; CI912; AD 810; CI 912
实验参考方法
In Vitro

In vitro activity: Zonisamide inhibits monoamine oxidase B (MAO-B) activity in vitro with an IC(50) of 25 μM.

In VivoZonisamide modifies dopamine (DA) activity, provides protection in ischemia mice models and influences antioxidant systems. Zonisamide attenuates the reduction in striatal contents of DA, its metabolite DOPAC and tyrosine hydroxylase (TH). Zonisamide (10 and 30 mg/kg) produces antihyperalgesic and antiallodynic effects in a dose-dependent manner, these effects are manifested by elevation of the withdrawal threshold in response to a thermal (plantar test) or mechanical (von Frey) stimulus, respectively.. Zonisamide produces antinociceptive effects against acute thermal and mechanical nociception in non-ligated mice. Zonisamide reduces the cortical infarction volume to 6% from 68% in vehicle-treated controls and the striatal volume to 8% from 78% in rats. Zonisamide also reduces neuronal necrosis in 5 hippocampal regions (the dentate gyrus, CA4, CA3, CA1, and the subiculum) in rats. Zonisamide causes increase in the quantity of EAAC-1 protein in hippocampus and cortex and down regulation of the GABA transporter GAT-1 in rats with hippocampal seizures. Zonisamide inhibits both the 50 mM KCl-evoked hippocampal glutamate release (AUC for 60 min) from 9.2 mM to 5.8 mM in urethane-anaesthetized rats, as well as the stimulatory effects of Ca2+ on KCl-evoked hippocampal glutamate release.
Animal modelMice and rats
Formulation & Dosage10 and 30 mg/kg
References

Exp Neurol. 2010 Feb;221(2):329-34; Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):107-14.